Corient Private Wealth LLC Sells 6,498 Shares of West Pharmaceutical Services, Inc. $WST

Corient Private Wealth LLC reduced its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 11.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,933 shares of the medical instruments supplier’s stock after selling 6,498 shares during the quarter. Corient Private Wealth LLC owned about 0.07% of West Pharmaceutical Services worth $11,144,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. SYM FINANCIAL Corp raised its position in shares of West Pharmaceutical Services by 5.1% during the 2nd quarter. SYM FINANCIAL Corp now owns 1,027 shares of the medical instruments supplier’s stock valued at $225,000 after acquiring an additional 50 shares during the last quarter. Benjamin Edwards Inc. increased its holdings in West Pharmaceutical Services by 1.7% in the second quarter. Benjamin Edwards Inc. now owns 3,021 shares of the medical instruments supplier’s stock valued at $661,000 after purchasing an additional 50 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in West Pharmaceutical Services by 4.0% during the second quarter. Parkside Financial Bank & Trust now owns 1,318 shares of the medical instruments supplier’s stock worth $288,000 after buying an additional 51 shares during the last quarter. MJP Associates Inc. ADV grew its position in shares of West Pharmaceutical Services by 2.7% during the 2nd quarter. MJP Associates Inc. ADV now owns 1,970 shares of the medical instruments supplier’s stock worth $431,000 after buying an additional 52 shares during the period. Finally, Pallas Capital Advisors LLC increased its stake in shares of West Pharmaceutical Services by 1.0% in the 2nd quarter. Pallas Capital Advisors LLC now owns 6,333 shares of the medical instruments supplier’s stock valued at $1,386,000 after acquiring an additional 62 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on WST. Redburn Partners set a $311.00 price target on shares of West Pharmaceutical Services in a research note on Monday, September 15th. Deutsche Bank Aktiengesellschaft set a $345.00 target price on shares of West Pharmaceutical Services and gave the stock a “buy” rating in a research note on Friday, October 24th. Zacks Research downgraded West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 23rd. KeyCorp boosted their price target on West Pharmaceutical Services from $325.00 to $350.00 and gave the company an “overweight” rating in a report on Friday, October 24th. Finally, UBS Group increased their price objective on West Pharmaceutical Services from $320.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, October 24th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, West Pharmaceutical Services has a consensus rating of “Moderate Buy” and an average price target of $342.20.

West Pharmaceutical Services Stock Down 0.3%

WST opened at $268.24 on Friday. West Pharmaceutical Services, Inc. has a 1-year low of $187.43 and a 1-year high of $348.90. The stock’s fifty day simple moving average is $273.92 and its 200 day simple moving average is $251.49. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07. The stock has a market cap of $19.30 billion, a PE ratio of 39.74, a price-to-earnings-growth ratio of 4.16 and a beta of 1.17.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.29. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The company had revenue of $804.60 million for the quarter, compared to analyst estimates of $788.42 million. During the same quarter last year, the company earned $1.85 earnings per share. The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. As a group, research analysts expect that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 4th. Investors of record on Wednesday, January 28th will be paid a $0.22 dividend. The ex-dividend date of this dividend is Wednesday, January 28th. This represents a $0.88 annualized dividend and a dividend yield of 0.3%. West Pharmaceutical Services’s payout ratio is currently 13.04%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.